Estimating the direct impact of new conjugate vaccines against invasive pneumococcal disease
Authors:
- W.P. HausdorffW.P. Hausdorff
- R. DaganRDR. Dagan
- F. BeckersFBF. Beckers
- L. SchuermanLSL. Schuerman
- 1 December 2009
- Vol. 27 (52) , 7257-7269
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline
This publication has 39 references indexed in Scilit:
- Changes in Serotypes and Antimicrobial Susceptibility of Invasive Streptococcus pneumoniae Strains in Cleveland: a Quarter Century of ExperienceJournal of Clinical Microbiology, 2008
- EFFECTIVENESS OF PNEUMOCOCCAL CONJUGATE VACCINE IN GREATER VANCOUVER, CANADA: 2004–2005The Pediatric Infectious Disease Journal, 2007
- Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control studyThe Lancet, 2006
- Effect of Introduction of the Pneumococcal Conjugate Vaccine on Drug-ResistantStreptococcus pneumoniaeNew England Journal of Medicine, 2006
- Progress in the prevention of pneumococcal infectionCanadian Medical Association Journal, 2005
- Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infantsVaccine, 2003
- Correlates of immunity for pneumococcal conjugate vaccinesVaccine, 2003
- Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate VaccineNew England Journal of Medicine, 2003
- Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in childrenThe Pediatric Infectious Disease Journal, 2000
- Which Pneumococcal Serogroups Cause the Most Invasive Disease: Implications for Conjugate Vaccine Formulation and Use, Part IClinical Infectious Diseases, 2000